The National Heart, Lung and Blood Institute (NHLBI) awards the remainder of a Fast Track Small Business Innovation Grant to Discovery Labs (DSCO +1.2%). The $2.4M total grant provided support for the development and Phase 2a clinical trial of Aerosurf, the company's investigational drug/device combination product for respiratory distress syndrome in premature infants. It provides KL4 surfactant therapy through nasal continuous positive airway pressure and enables the infant to potentially avoid endotracheal intubation.
NHLBI awards final $1.9M of grant to Discovery Labs
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs